Source disclosure: January 27, 2026
Maruto Sangyo [7894.F]
TOKYO, Jan 27 (Pulse News Wire) -- Maruto Sangyo Co., Ltd. (78940.T), represented by President Masayuki Sugahara, has decided to tender its entire holdings of Koshin Pharmaceutical Co., Ltd. (4530) shares in response to a public offer initiated by Taiyo Kobo Corporation. This decision was made during today's board meeting and is expected to result in a special gain of approximately ¥349 million being recorded as investment securities sale proceeds in the company’s individual and consolidated financial statements for the fiscal year ending February 2026.
Maruto Sangyo currently holds 76,539 ordinary shares of Koshin Pharmaceutical, including about 53,539 shares held through the Koshin Pharmaceutical Trading Association. The company will tender all these shares in the public offering. If the transaction goes ahead as planned, it will sell its entire stake in Koshin Pharmaceutical at an estimated price of ¥6,082 per share, resulting in a total sale value of approximately ¥465 million.
The public offering period began on January 7, 2026, and will continue until February 19, 2026. Settlement is scheduled to start on February 27, 2026. According to the terms of the public offer, Koshin Pharmaceutical's board of directors has expressed approval, and the conditions set forth, such as the purchase price, have been deemed reasonable by Maruto Sangyo.
Regarding future prospects, Maruto Sangyo anticipates that the sale of its Koshin Pharmaceutical shares will contribute to a special gain of ¥349 million in the second month of the fiscal year ending February 2026. However, while this anticipated profit may impact the parent company's net income attributable to shareholders for the same period, the company stated that due to ongoing assessments of other factors, there would be no changes to the previously announced forecast released on April 14, 2025. Maruto Sangyo added that it will disclose any updates regarding its earnings outlook once they become definitive.
AI-translated content. 🟢 Confidence: High See terms • Original filing